Heparin during endovascular stroke treatment seems safe - 11/10/19
pages | 5 |
Iconographies | 1 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Background and purpose |
the effect of intravenous heparin during mechanical thrombectomy for acute ischemic stroke is not clear. We aimed to study efficacy and safety of heparin use during endovascular stroke treatment in a real-world setting.
Materials and methods |
patients with anterior circulation stroke were divided, based on the use of intraprocedural heparin, in those treated and those untreated. Main outcomes were successful reperfusion defined as a TICI Score ≥ 2b, 3-month functional independence defined as a modified Rankin Scale ≤ 2, symptomatic intracranial hemorrhage (sICH) and mortality.
Results |
361 patients were eligible for analysis; 200 were (H+) and 161 (H-). The (H-) group showed higher age and ASPECTS (74 ± 14 vs. 68.9 ± 12.2; P = 0.001; 8 ± 1.6 vs. 7.4 ± 2.1; P = 0.009) without differences in vascular risk factors. Heparin untreated patients showed a shorter onset-to-reperfusion time (271 ± 57.6 min vs. 309 ± 102.2 min; P < 0.001). No differences were found in 3-month functional independence, sICH and mortality whereas the rate of successful reperfusion was higher in the (H-) group. After logistic regression analysis successful reperfusion was independently associated with CT ASPECTS (OR: 1.16; 95%CI 1.01–1.35; P = 0.040) but inversely associated with the use of heparin (OR: 0.48; 95% CI 0.24–0.98; P = 0.045).
Conclusions |
Heparin use during mechanical thrombectomy for anterior circulation acute ischemic stroke in a real world setting is safe.
Le texte complet de cet article est disponible en PDF.Keywords : Heparin, Endovascular stroke treatment, Outcome
Plan
Vol 46 - N° 6
P. 373-377 - novembre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?